Sugi Predict

Sugi Predict / Compounds / SCHEMBL817399

SCHEMBL817399

SCHEMBL817399

C#CC(O)CCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ANPEP P15144 2/20 0.43
▸ ERAP1 Q9NZ08 2/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ ERAP2 Q6P179 1/20 0.43
▸ ACP3 P15309 1/20 0.42
▸ SLC6A2 P23975 2/20 0.41
▸ SLC6A4 P31645 2/20 0.41
▸ SLC6A3 Q01959 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ TSHR P16473 2/20 0.41
▸ CNR2 P34972 1/20 0.41
▸ DPP4 P27487 1/20 0.40
▸ MMP2 P08253 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ MMP12 P39900 1/20 0.40
▸ MMP13 P45452 1/20 0.40
▸ MMP14 P50281 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL817464 1.00 ANPEP (0.43) ANPEPERAP1TDP1ERAP2ACP3
SCHEMBL15873967 0.88 GRIK1 (0.42) TDP1SLC6A3KCNH2
SCHEMBL15142215 0.80 CYP1A2 (0.42) TDP1KCNH2DPP4
SCHEMBL11344441 0.80 TAAR1 (0.42) SLC6A4
SCHEMBL31752269 0.80 TAAR1 (0.42) KCNH2
SCHEMBL3997283 0.79 CTSC (0.44) ANPEPERAP1TDP1ERAP2ACP3
SCHEMBL2163440 0.79 CTSC (0.44) ANPEPERAP1TDP1ERAP2ACP3
SCHEMBL4323888 0.79 CTSC (0.44) ANPEPERAP1TDP1ERAP2ACP3
SCHEMBL27660875 0.79 DPP4 (0.47) ANPEPERAP1TDP1ERAP2ACP3
SCHEMBL9793910 0.78 MAOB (0.47) SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622947-A1 ENAMINE N-OXIDE TOOLS FOR TARGET IDENTIFICATION APPLICATIONS Dana-Farber Cancer Institute, Inc. (US) 2025-10-01 — — EP disclosed
WO-2024112754-A1 ENAMINE N-OXIDE TOOLS FOR TARGET IDENTIFICATION APPLICATIONS DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-05-30 — — WO disclosed
CN-115677549-A Preparation method of bimatoprost chiral isomer 神隆医药（常熟）有限公司 2023-02-03 — — CN disclosed
CN-114276247-A 1,5-enyne ester chiral compound and synthesis method thereof 华中师范大学 2022-04-05 — — CN disclosed
EP-2864308-B1 (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues UNIV BRISTOL (GB) 2016-10-19 — — EP disclosed
US-9242954-B2 Lactol and acetal intermediates for making prostaglandins UNIVERSITY OF BRISTOL (GB) 2016-01-26 — — US disclosed
EP-2943722-A1 PROTECTIVE COATING FOR LED LAMP Cree, Inc. (US) 2015-11-18 — — EP disclosed
US-20150158837-A1 Compound And Method TOPOKINE THERAPEUTICS, INC. 2015-06-11 — — US disclosed
EP-2274266-B1 PROCESS FOR THE PREPARATION OF PROSTAGLANDIN ANALOGUES AND INTERMEDIATES THEREOF SCINOPHARM TAIWAN LTD (TW) 2014-10-15 — — EP disclosed
WO-2014110211-A1 PROTECTIVE COATING FOR LED LAMP CREE, INC. (US) 2014-07-17 — — WO disclosed
EP-0589965-B1 ORGANOBORON REAGENTS FOR THE PREPARATION OF UNSUBSTITUTED PROPARGYLIC ALCOHOLS MERRELL PHARMA INC (US) 1997-01-08 — — EP disclosed
EP-0255098-B1 Novel 8-(lower alkyl) bicyclo [4.2.0] octane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1991-05-29 — — EP disclosed
US-4983627-A Treating atherosclerosis, thrombosis and vasospasms; anticholesterol,-secretory,-ulcer and hypotensive agents SYNTEX (U.S.A.) INC. (US) 1991-01-08 — — US disclosed
EP-0196617-B1 [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same SYNTEX (U.S.A.) INC. (US) 1989-05-31 — — EP disclosed
US-4735966-A ANTICOAGULANTS, VASODILATORS, HYPOTENSIVE AND ANTICHOLESTEROL AGENTS SYNTEX (U.S.A.) INC. (US) 1988-04-05 — — US disclosed
EP-0257609-A2 Novel substituted (4.2.0)Bicyclooctane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1988-03-02 — — EP disclosed
EP-0255098-A1 Novel 8-(lower alkyl) bicyclo [4.2.0] octane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1988-02-03 — — EP disclosed
US-4678805-A Novel 8-(lower alkyl)bicyclo[4.2.0]octane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1987-07-07 — — US disclosed
EP-0196617-A1 [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same SYNTEX (U.S.A.) INC. (US) 1986-10-08 — — EP disclosed
US-4608388-A Novel [4,2,0]bicyclooctane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1986-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158837-A1 Compound And Method CYP4A11, NR1H2, NR1H3 ANPEP 4112/4885ERAP1 3984/4885TDP1 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.